- Updated data from a Phase 1 clinical trial, SCOUT, assessing Loxo Oncology's (LOXO +2.1%) larotrectinib in pediatric cancer patients showed a significant treatment effect. The results were presented today at the American Association for Cancer Research Special Conference on Pediatric Cancer Research in Atlanta, GA.
- The overall response rate was 93% (n=14/15) in TRK fusion-evaluable patients, including 12 partial responders and two complete responders. The other patient had stable disease.
- Larotrectinib (LOXO-101) inhibits a group of enzymes called tropomyosin receptor kinases (TRK), a group of proteins that plays a key role in cellular communications. Cancers hijack these communication pathways to send messages to cells to grow, change or survive. Those characterized by these alterations, termed NTRK fusions, are the therapeutic targets for the drug.
- The company is co-developing and will co-commercialize larotrectinib with Bayer (DE:BAYGN).
- Previously: Loxo teams up with Bayer to develop TRK inhibitors; shares up 6% premarket (Nov. 14)
- Now read: Loxo Oncology Is A Buy Ahead Of Data Update
Original article